Axsome Therapeutics (AXSM) EBIAT: 2022-2025
Historic EBIAT for Axsome Therapeutics (AXSM) over the last 4 years, with Sep 2025 value amounting to -$47.2 million.
- Axsome Therapeutics' EBIAT rose 26.89% to -$47.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$229.5 million, marking a year-over-year increase of 26.19%. This contributed to the annual value of -$287.2 million for FY2024, which is 20.05% down from last year.
- Per Axsome Therapeutics' latest filing, its EBIAT stood at -$47.2 million for Q3 2025, which was up 1.55% from -$48.0 million recorded in Q2 2025.
- In the past 5 years, Axsome Therapeutics' EBIAT registered a high of -$11.2 million during Q1 2023, and its lowest value of -$98.7 million during Q4 2023.
- Moreover, its 3-year median value for EBIAT was -$64.6 million (2024), whereas its average is -$61.9 million.
- Its EBIAT has fluctuated over the past 5 years, first soared by 71.69% in 2023, then crashed by 509.35% in 2024.
- Over the past 4 years, Axsome Therapeutics' EBIAT (Quarterly) stood at -$61.2 million in 2022, then slumped by 61.09% to -$98.7 million in 2023, then increased by 24.06% to -$74.9 million in 2024, then rose by 26.89% to -$47.2 million in 2025.
- Its last three reported values are -$47.2 million in Q3 2025, -$48.0 million for Q2 2025, and -$59.4 million during Q1 2025.